Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model
摘要:
Autotaxin (ATX) catalyzes the hydrolysis of lysophosphatidylcholine (LPC) generating the lipid mediator lysophosphatidic acid (LPA). Both ATX and LPA are involved in various pathological inflammatory conditions, including fibrosis and cancer, and have attracted great interest as medicinal targets over the past decade. Thus, the development of novel potent ATX inhibitors is of great importance. We have developed a novel class of ATX inhibitors containing the zinc binding functionality of hydroxamic acid. Such novel hydroxamic acids that incorporate a non-natural delta-amino acid residue exhibit high in vitro inhibitory potency over ATX (IC50 values 50-60 nM). Inhibitor 32, based on delta-norleucine, was tested for its efficacy in a mouse model of pulmonary inflammation and fibrosis induced by bleomycin and exhibited promising efficacy. The novel hydroxamic ATX inhibitors provide excellent tools for the study of the role of the enzyme and could contribute to the development of novel therapeutic agents for the treatment of fibrosis and other chronic inflammatory diseases.
[EN] PHENOLIC COMPOUND, SKIN-WHITENING COSMETIC COMPOSITION COMPRISING SAME, AND SKIN-WHITENING COSMETIC PRODUCT<br/>[FR] COMPOSÉ PHÉNOLIQUE, COMPOSITION COSMÉTIQUE DE BLANCHIMENT DE LA PEAU LE COMPRENANT, ET PRODUIT COSMÉTIQUE DE BLANCHIMENT DE LA PEAU<br/>[KO] 페놀계 화합물, 이를 포함하는 피부미백용 화장품 조성물 및 피부미백 화장품
申请人:CELLINBIO CO LTD
公开号:WO2021125418A1
公开(公告)日:2021-06-24
본 발명은 하기 화학식 1의 구조를 가지는 페놀계 화합물 및 이의 화장품공학적으로 허용되는 염을 유효성분으로 함유하는 피부미백용 화장품 조성물과, 상기 조성물을 포함하는 피부미백용 화장품에 관한 것이다. 본 발명의 페놀계 화합물은 피부 미백 활성이 우수할 뿐만 아니라, 세포 독성이 없으며, 활성산소를 억제하여, 인체에 무해하여 안전성이 뛰어나다. [화학식 1]
Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit <i>in Vivo</i> Efficacy in a Pulmonary Fibrosis Model
作者:Aikaterini Nikolaou、Ioanna Ninou、Maroula G. Kokotou、Eleanna Kaffe、Antreas Afantitis、Vassilis Aidinis、George Kokotos
DOI:10.1021/acs.jmedchem.8b00232
日期:2018.4.26
Autotaxin (ATX) catalyzes the hydrolysis of lysophosphatidylcholine (LPC) generating the lipid mediator lysophosphatidic acid (LPA). Both ATX and LPA are involved in various pathological inflammatory conditions, including fibrosis and cancer, and have attracted great interest as medicinal targets over the past decade. Thus, the development of novel potent ATX inhibitors is of great importance. We have developed a novel class of ATX inhibitors containing the zinc binding functionality of hydroxamic acid. Such novel hydroxamic acids that incorporate a non-natural delta-amino acid residue exhibit high in vitro inhibitory potency over ATX (IC50 values 50-60 nM). Inhibitor 32, based on delta-norleucine, was tested for its efficacy in a mouse model of pulmonary inflammation and fibrosis induced by bleomycin and exhibited promising efficacy. The novel hydroxamic ATX inhibitors provide excellent tools for the study of the role of the enzyme and could contribute to the development of novel therapeutic agents for the treatment of fibrosis and other chronic inflammatory diseases.
Tsatsas,G. et al., Bulletin de la Societe Chimique de France, 1964, p. 2615 - 2617